Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Cancelled Post Market
Current status date:
2021-04-09
Original market date: See footnote 1
2009-07-01
Lot number: See footnote 2
CAMR205
Expiry date: See footnote 2
2023-08-31
Product name:
ERWINASE
Description:
ERWINIA CHRYSANTHEMI DERIVED
DIN:
02237815
Product Monograph/Veterinary Labelling:
Date:
2016-08-30
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
JAZZ PHARMACEUTICALS FRANCE SAS
84 Quai Charles De Gaulle City One
Lyon
Auvergne-Rhone-Alpes
France
69006
Class:
Human
Dosage form(s):
Powder For Solution
Route(s) of administration:
Subcutaneous , Intravenous , Intramuscular
Number of active ingredient(s):
1
Schedule(s):
Prescription , Schedule D
American Hospital Formulary Service (AHFS): See footnote 3
10:00.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
L01XX02 ASPARAGINASE
Active ingredient group (AIG) number:See footnote5
0109328001
Active ingredient(s) | Strength |
---|---|
ASPARAGINASE | 10000 UNIT / VIAL |